Sanofi SA (NASDAQ:SNY) announced its plans to spin off its consumer healthcare business as the French pharmaceutical company ...

Also Read: Sanofi’s Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows. Sarclisa is the first anti-CD38 therapy in combination with standard-of-care VRd ...

The best tablets for students, like the top pick, the Apple iPad Pro M4 can be a great supplementary piece to a companion laptop. It can streamline your workflow in one powerful, portable package ...

We also got Houman here who is Sanofi EVP and Head of Research and ... 60 milligrams orally, one tablet daily, or a matching placebo and followed over time. Clinical assessments were conducted ...

Image credit: LCV / Shutterstock. Sanofi is eyeing global regulatory approval for tolebrutinib after releasing positive Phase III data in non-relapsing secondary progressive multiple sclerosis (MS), ...

Access all your entertainment and work needs with this high-quality 10-inch tablet. By Lilian Gonzalez editor All products and services featured are independently chosen by editors. However ...

You can now save $450 on this AT&T variant for a limited time. This is the best tablet that you can currently purchase in 2024. Not only does it sit at the top of our list when it comes to Android ...

If you’re looking for a cheap tablet, chances are you’ll be considering an Amazon Fire Tab. I’ve come to think of Amazon’s tablet range as a reliable entry point to the tech world. They’re dependable ...

If you’re in the market for a tablet, it’s worth considering a few options beyond the popular models from Apple and Samsung. One of those is, of course, Amazon, which has emerged as a major player at ...

FILE - In this image provided by the North Fork Correctional Center in Sayre, Okla., on Tuesday, June 9, 2021, an inmate Byron Robinson works on a tablet, which are being provided for free to Oklahoma ...

Panacea Biotec has resolved a patent infringement lawsuit with Sanofi Healthcare concerning its EasySix hexavalent vaccine. Under the settlement, Sanofi will refrain from launching its Shan6 ...

Panacea Biotec has settled a patent infringement case with Sanofi Healthcare India over a hexavalent vaccine. Sanofi will not launch its Shan6 vaccine in India and will withdraw its opposition to ...